Clinical observations with Péflacine

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Hospital-acquired infections (HAIs) pose significant treatment challenges.
• Pefloxacin is an antibiotic with potential for treating severe infections.
• Existing data on pefloxacin's efficacy in HAIs may be inconsistent.

Purpose of the Study:

• To evaluate the efficacy and safety of pefloxacin in treating severe hospital-acquired infections.
• To compare the effectiveness of oral versus intravenous pefloxacin administration.
• To document the incidence of side-effects associated with pefloxacin treatment.

Main Methods:

• Clinical study involving patients with severe hospital-acquired infections.
• Treatment administered via oral and intravenous routes.
• Infections targeted included urinary tract, hepatic-biliary tract, and lower respiratory tract.
• Adverse events were systematically recorded.

Main Results:

• Pefloxacin demonstrated successful treatment outcomes in severe HAIs.
• No significant difference in efficacy was observed between oral and intravenous pefloxacin.
• Side-effects were reported in only 10% of patients, indicating a favorable safety profile.

Conclusions:

• Pefloxacin is an effective and safe therapeutic option for severe hospital-acquired infections.
• Both oral and intravenous routes of administration are viable for pefloxacin.
• Further research may explore pefloxacin's role in specific infection types.